These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1193 related items for PubMed ID: 25381429

  • 1. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
    Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC, Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group.
    J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
    [Abstract] [Full Text] [Related]

  • 2. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H, Lee SM, Manno RL, Seo P, Geetha D.
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [Abstract] [Full Text] [Related]

  • 3. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
    Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Ding L, Iklé D, Villareal M, Lim N, Brunetta P, Fervenza FC, Monach PA, Stone JH, Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.
    Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
    [Abstract] [Full Text] [Related]

  • 4. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U, RAVE-ITN Research Group.
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
    Aqeel F, Xu L, Salas A, Wen Y, Eid SM, Geetha D.
    Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
    [Abstract] [Full Text] [Related]

  • 6. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant.
    Murakami C, Manoharan P, Carter-Monroe N, Geetha D.
    Transpl Int; 2013 Dec; 26(12):1225-31. PubMed ID: 24118474
    [Abstract] [Full Text] [Related]

  • 7. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D, Hruskova Z, Segelmark M, Hogan J, Morgan MD, Cavero T, Eriksson P, Seo P, Manno RL, Dale J, Harper L, Tesar V, Jayne DR.
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [Abstract] [Full Text] [Related]

  • 8. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
    Kant S, Habbach A, Gapud EJ, Manno RL, Gattu R, Seo P, Geetha D.
    Am J Nephrol; 2019 Apr; 50(5):386-391. PubMed ID: 31593967
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
    Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Sejismundo LP, Mieras K, Iklé D, Jepson B, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH, Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.
    Arthritis Rheum; 2013 Sep; 65(9):2441-9. PubMed ID: 23754238
    [Abstract] [Full Text] [Related]

  • 10. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB, Furuta S, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh M, Westman K, Jayne DR, European Vasculitis Society (EUVAS).
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
    Casal Moura M, Irazabal MV, Eirin A, Zand L, Sethi S, Borah BJ, Winters JL, Moriarty JP, Cartin-Ceba R, Berti A, Baqir M, Thompson GE, Makol A, Warrington KJ, Thao V, Specks U, Fervenza FC.
    J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
    [Abstract] [Full Text] [Related]

  • 12. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L, French Vasculitis Study Group.
    N Engl J Med; 2014 Nov 06; 371(19):1771-80. PubMed ID: 25372085
    [Abstract] [Full Text] [Related]

  • 13. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
    Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Iklé D, Villarreal M, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH, Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.
    Arthritis Rheumatol; 2014 Nov 06; 66(11):3151-9. PubMed ID: 25047592
    [Abstract] [Full Text] [Related]

  • 14. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
    Alberici F, Jayne DR.
    Nephrol Dial Transplant; 2014 Jun 06; 29(6):1151-9. PubMed ID: 24126571
    [Abstract] [Full Text] [Related]

  • 15. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M, Gunnarsson I, Bratt J, Bruchfeld A.
    Scand J Rheumatol; 2012 Mar 06; 41(2):116-9. PubMed ID: 22118245
    [Abstract] [Full Text] [Related]

  • 16. Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?
    Morel P, Karras A, Porcher R, Belenfant X, Audard V, Rafat C, Hanouna G, Beaudreuil S, Vilain C, Hummel A, Terrier B, Pillebout E, Groh M, Jouenne R, Dhote R, Fain O, Ponsoye M, Noel N, Limal N, Puéchal X, Le Jeunne C, Guillevin L, Mouthon L, Régent A.
    Rheumatology (Oxford); 2022 Oct 06; 61(10):4056-4064. PubMed ID: 35108368
    [Abstract] [Full Text] [Related]

  • 17. Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?
    Specks U.
    Nephrol Dial Transplant; 2015 Jul 06; 30(7):1083-7. PubMed ID: 25999375
    [Abstract] [Full Text] [Related]

  • 18. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
    Chasseur P, Blockmans D, von Frenckell C, Nicolas JB, Regniers C, Vandergheynst F.
    Acta Clin Belg; 2020 Jun 06; 75(3):163-169. PubMed ID: 30767717
    [Abstract] [Full Text] [Related]

  • 19. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
    Shah S, Hruskova Z, Segelmark M, Morgan MD, Hogan J, Lee SK, Dale J, Harper L, Tesar V, Jayne DR, Geetha D.
    Am J Nephrol; 2015 Jun 06; 41(4-5):296-301. PubMed ID: 26044574
    [Abstract] [Full Text] [Related]

  • 20. Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial.
    Miloslavsky EM, Niles JL, Wallace ZS, Cortazar FB, Fernandes A, Laliberte K, Stone JH.
    Semin Arthritis Rheum; 2018 Oct 06; 48(2):288-292. PubMed ID: 29530330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.